Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Vinay Prasad(University of California, San Francisco), Sham Mailankody(Memorial Sloan Kettering Cancer Center)
Cited by 497
Related Papers
The high price of anticancer drugs: origins, implications, barriers, solutions
|Nature Reviews Clinical Oncology|2017|430
GPRC5D-Targeted CAR T Cells for Myeloma
|New England Journal of Medicine|2022|383
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
|JAMA Otolaryngology–Head & Neck Surgery|2014|301
Five Years of Cancer Drug Approvals
|JAMA Oncology|2015|287